Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Mecasermin

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Mecasermin used for?
The FDA-approved label (Increlex, Eton Pharmaceuticals, Inc., May 18, 2026) says: “INCRELEX (mecasermin) injection is indicated for the treatment of growth failure in pediatric patients 2 years of age and older with severe primary IGF- 1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. Limitations of use: INCRELEX is not a substitute to GH for approved GH indications. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Mecasermin have a boxed warning?
No. None of the 2 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Mecasermin?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Mecasermin been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Mecasermin?
2 companies list prescription products of Mecasermin in the FDA NDC Directory, including Eton Pharmaceuticals, Inc. and Ipsen Biopharmaceuticals, Inc..

What Mecasermin is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

INCRELEX (mecasermin) injection is indicated for the treatment of growth failure in pediatric patients 2 years of age and older with severe primary IGF- 1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. Limitations of use: INCRELEX is not a substitute to GH for approved GH indications. …

— FDA label: Increlex, Eton Pharmaceuticals, Inc., effective May 18, 2026. Read the full label on DailyMed →

The FDA has 2 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

0 of 2 FDA labels for this medicine have a boxed warning.

Forms and how it is given

Dosage formsInjection · Injection, solution
RouteSubcutaneous
Prescription products2 in the FDA NDC Directory
Brand namesIncrelex

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
BLA021839
INCRELEX
Ipsen IncAugust 30, 2005 11, latest July 9, 2025
2025: Labeling · 2024: Efficacy · 2023: Labeling

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)604806, 615882
SPL set ID of the quoted labeld5b2b0e1-c523-468d-9a0b-4ae4e4a8dbce
FDA labels (SPL)2
FDA applicationsBLA021839
Active ingredients (FDA)MECASERMIN

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Increlex, Eton Pharmaceuticals, Inc., effective May 18, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers